Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2022 pubmed 1 citations

Preparation and Characterization of PLG Microparticles by the Multiple Emulsion Method for the Sustained Release of Proteins.

Yenying. Arphaphat A; Tangamatakul. Krissana K; Supanchart. Chayarop C; Jenvoraphot. Thannaphat T; Manokruang. Kiattikhun K; Worajittiphon. Patnarin P; Punyodom. Winita W; Daranarong. Donraporn D

Key Findings

  • PLG microparticles released BSA steadily over about 8 weeks after an initial burst
  • Optimal formulation used 8% PLG, 0.25% PVA, and 8% BSA for best encapsulation efficiency
  • Encapsulating LL‑37 under the same conditions showed high variability and poor reproducibility

Practical Outcomes

  • The study shows that PLG particles can sustain protein release, but the current method isn’t reliable for LL‑37. DIY biohackers would need to develop more consistent encapsulation techniques before applying this for peptide delivery.

Summary

Scientists made tiny PLG particles that can slowly release proteins like a growth factor for up to two months, but when they tried the same trick with the peptide LL‑37, the results were inconsistent and hard to reproduce, meaning it’s not a ready‑to‑use method for hobbyists yet.

Abstract

Rapid release and diminished stability are two of the limitations associated with the growth factors that are essentially used in dental applications. These growth factors are employed to enhance the quality and quantity of tissue or bone matter during regeneration. Therefore, drug delivery devices and systems have been developed to address these limitations. In this study, bovine serum albumin (BSA), as a representative growth factor, was successfully sustained by encapsulation with the medium-absorbable copolymer, poly(L-lactide-<i>co</i>-glycolide) (PLG) 70:30% mol, via the multiple emulsion method. Different PLG, PVA, and BSA concentrations were used to investigate their effects on the BSA encapsulation efficiency. The suitable ratios leading to a better characterization of microparticles and a higher encapsulation efficiency in producing encapsulated PLG microparticles were 8% (<i>w</i>/<i>v</i>) of PLG, 0.25% (<i>w</i>/<i>v</i>) of PVA, and 8% (<i>w</i>/<i>v</i>) of BSA. Furthermore, an in vitro release study revealed a bursting release of BSA from the encapsulated PLG microsphere in the early phase of development. Subsequently, a gradual release was observed over a period of eight weeks. Furthermore, to encapsulate LL-37, different proteins were used in conjunction with PLG under identical conditions with regard to the loading efficiency and morphology, thereby indicating high variations and poor reproducibility. In conclusion, the encapsulated PLG microparticles could effectively protect the protein during encapsulation and could facilitate sustainable protein release over a period of 60 days. Importantly, an optimal method must be employed in order to achieve a high degree of encapsulation efficiency for all of the protein or growth factors. Accordingly, the outcomes of this study will be useful in the manufacture of drug delivery devices that require medium-sustained release growth factors, particularly in dental treatments.

Study Information

Provider

pubmed

Year

2022

Date

2022-10-18T00:00:00.000Z

DOI

10.3390/mi13101761

Citations

1

References

33